Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial
JAMA Cardiology
The paper
Ostrominski JW, Plutzky J, Scirica BM et al.
JAMA Cardiology · 16 Sep 2026
More on GLP-1 and incretin signalling
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Cardiology and Therapy · 4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026
Social context predicts heart risks despite normal biomarkers
medRxiv · 4 Oct 2026